Celularity to Manufacture Six Licensed Biomaterials and Three Pipeline Devices with NEXGEL by April 2026
Celularity licensed six established biomaterial products, including Biovance and Centaflex, plus three 510(k) pipeline programs—SPARK, FUSE, and ORCHID—to NEXGEL under a commercialization partnership set to close by April 15, 2026. The company will be the exclusive manufacturer at its FDA-compliant Florham Park, NJ facility to support scalable production.
1. Partnership Overview
Celularity and NEXGEL have entered a strategic commercialization partnership where Celularity licenses six established biomaterial products and three 510(k) pipeline programs. The transaction, expected to close by April 15, 2026, grants NEXGEL marketing rights and positions Celularity as the exclusive manufacturer for the portfolio.
2. Licensed Products
The licensed portfolio includes Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl, and Centaflex, all of which are currently commercial-stage products serving wound care, orthopedics, and additional indications. These products provide an immediate revenue stream and broaden NEXGEL’s existing biomaterials franchise.
3. Pipeline Opportunities
Celularity’s three pipeline programs—SPARK, FUSE, and ORCHID—are being developed via the 510(k) medical device pathway and could disrupt markets with next-generation placental-derived biomaterials. Successful clearance of these programs would expand Celularity’s long-term growth prospects in regenerative medicine.
4. Manufacturing Capacity
All licensed and pipeline products will be manufactured exclusively at Celularity’s FDA-compliant facility in Florham Park, New Jersey. The site’s vertically integrated infrastructure is designed for scalable, pharmaceutical-grade production to support both current commercial-stage biomaterials and future cell therapy products.